Prometheus Biosciences, Inc. (RXDX)
|Net Income (ttm)||n/a|
|Trading Day||May 14|
|Day's Range||16.65 - 17.69|
|52-Week Range||16.11 - 30.62|
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.
Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.
Steven Cohen ( Trades , Portfolio ) has revealed a new buy into Prometheus Biosciences Inc. (NASDAQ:RXDX) alongside an addition to his position in Curis Inc. (NASDAQ:CRIS) according to GuruFocus Real-Ti...
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.
Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purc...
SAN DIEGO, March 16, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercializat...
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development,...
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, filed on Friday with the SEC to raise up to $125 million in an initial public offering.
Prometheus Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.
Prometheus Biosciences is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). We leverage our proprietary precision medicine platform, Prometheus360™, which includes one of the world’s largest gastrointestinal (GI) bioinformatics databases, to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, we are developing ... [Read more...]
|IPO Date |
Mar 12, 2021
Mark C. McKenna
|Stock Exchange |
|Ticker Symbol |
In 2020, RXDX's revenue was $1.23 million, an increase of 9.93% compared to the previous year's $1.12 million. Losses were -$37.14 million, 24.9% more than in 2019.
The average 12-month stock price forecast for RXDX is 32.25, which is an increase of 91.74% from the latest price.